Shanghai RAAS (002252.SZ) subsidiary's Protein C receives drug clinical trial approval

date
16/11/2026
Zhitong Finance APP news, Shanghai RAAS (002252.SZ) issued an announcement. Recently, the company's wholly-owned subsidiary Guangxi RAAS Biopharmaceutical Co., Ltd. (referred to as "Guangxi RAAS") received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration. The National Medical Products Administration agreed that the "Protein C" declared by Guangxi RAAS may conduct clinical trials for the treatment of patients with severe congenital protein C deficiency. As a domestically pioneered blood product for the treatment of rare diseases, if this drug can be successfully approved for marketing, it can improve the company's comprehensive plasma utilization rate, enrich the company's production lines, optimize product layout, and enhance the company's competitiveness in the field of plasma-derived and high value-added products.